Volume: 32 Issue: 1, 3/27/25

Year: 2025

Erratum

Research Articles

Reviews

Coşkun Silan
Prof. Dr. Coşkun SİLAN ÇANAKKALE ONSEKİZ MART ÜNİVERSİTESİ
Medical Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics
Default avatar
Prof. Dr. Evrim ERDEMOGLU SULEYMAN DEMIREL UNIVERSITY, SCHOOL OF MEDICINE
Obstetrics and Gynaecology, Gynecologic Oncology Surgery
Evrim Erdemoğlu
Prof. Dr. Evrim ERDEMOĞLU SÜLEYMAN DEMİREL ÜNİVERSİTESİ

Evrim Erdemoglu, MD, Prof.
born in Ankara Turkey 23.07.1974
Married to Dr. Ebru Erdemoglu (Perinatologist in Obstetrics and Gynecology De- partment, SDU University), 2 Children
Adress: Turan Mah. 126. Cad. Mehmet Bilginer Sitesi B Blok No14, Isparta, Turkey GSM: +905052724344
E-mail: evrimmd@yahoo.com


Languages
Turkish
English
German B2 (Goethe Institute Examination)
Norwegian B1

Focus of Academic Area; Laparoscopic surgery, Ovarian cancer, Cytoreduction, HIPEC, cervical cancer, colposcopy, endometrial cancer, vulvar cancer, vulvar reconstruction, pelvic exenteration






Educational Activities
2015-2016 Ovarian Cancer Center, IEO,European Instute of Oncology, Milano Italy; I had the Scholarship and Grant by Gugole Grant, Milano, Italy.
2010 Observer for 3 month, Campus Benjamin Franklin, Director; Prof. Schneider, Charite Universität Berlin Germany
2008 Observer for 3 month, Campus Benjamin Franklin, Director; Prof. Schneider, Charite Universität Berlin Germany
1998-2003 Obstetrics and Gynecology Residency in Zekai Tahir Burak Womens Hospital, Ankara
1992-1998 Gazi University Medical Faculty
TED Ankara College (1992-)

Academic Activities & Work

2016 Head of division of Gynecologic Oncology,in Süleyman Demirek University,
2016 Prof. in in Suleyman Demirel University, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
2010-2015 Assoc. Prof. in Suleyman Demirel University, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
2007-2010 Assit Prof. in Suleyman Demirel University, Department of Obstetrics and Gynecology
2004-2007 Assit Prof. in Yüzüncu yıl University Department of Obstetrics and Gynecology


BOOK CHAPTERS
International Book Chapters
1.Schneider A, Köhler C, Erdemoglu E. Laparoscopy in Gynecologic Oncology. in
Gynecologic Oncology. ed. George Peltuci, 2010 2.Schneider A, Erdemoglu E. Radical Trachelectomy.2nd edition 2011, chapter 86.;
522-526.

2 An Update on Treatment and Approach to Uterine Carcinosarcoma. Erdemoglu E, İlyas T, Ozturk V. Türkiye Klinikleri; Discussional Topics in Gynecologic Oncology, 2021

3 Ozturk V, Turan I, Erdemoglu E. Genetic Profile and Clinical Significance of Low-Grade Serous Ovarian Cancers. Hereditary Gynecological Cancers and the Role of Molecular Pathology in Prognosis and Treatment. Türkiye Klinikleri; 2022.

4 Erdemoglu E. Management of Peritoneal Disease in Epithelial Ovarian Cancer and Cytoreductive Surgery-HIPEC. Cytoreduction, Türkiye Klinikleri; 2017
.

PUBLICATIONS in SCI & SCI-E
1. Vercellino GF, Erdemoglu E, Lichtenberg P, Muallem MZ, Richter R, Abu- Rustum NR, Plante M, Lécuru F, Greggi S, Monk BJ, Sagae S, Denkert C, Keller M, Alhakeem M, Hellriegel M, Dückelmann AM, Chiantera V, Sehouli A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer. J. Arch Gynecol Obstet. 2019 Jul;300(1):191-199. doi: 10.1007/ s00404-019-05164-2. Epub 2019 Apr 21.
2. Schneider A, Köhler C, Erdemoglu E. Current developments for pelvic exenteration in gy- necologic oncology. Curr Opin Obstet Gynecol. 2009;21(1):4-9.
3.Evrim Erdemoglu, Yakup Yalçın, Kemal K. Bozkurt, Ebru Erdemoglu. Surgical Staging in Low Risk Stage IA Endometroid Endometrial Cancers. EJGO; 2017;1:80-84
4.Schneider A, Petry U, Erdemoglu E, Paavonen J. HPV-based screening for pre- vention of invasive cervical cancer. Lancet. 2014 12;383(9925):1294-5
5.Vercellino GF, Erdemoglu E, Kyeyamwa S, Drechsler I, Vasiljeva J, Cichon G, Schneider A. Evaluation of the VITOM in digital high-
definition video exocol- poscopy. J Low Genit Tract Dis. 2011;15(4):292-5
6.Vercellino GF, Koehler C, Erdemoglu E, Mangler M, Lanowska M, Malak AH, Schneider A, Chiantera V. Laparoscopic pelvic lymphadenectomy in 32 pregnant
patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer. 2014 ;24(2):364-71.
7.Vercellino GF, Erdemoglu E, Chiantera V, Vasiljeva K, Drechsler I, Cichon G, Schneider A, Böhmer G. Validity of the colposcopic criteria inner border sign, ridge sign, and rag sign for detection of high-grade cervical intraepithe- lial neoplasia. Obstet Gynecol. 2013 ;121(3):624-31.
8.Vercellino G, Erdemoglu E, Joe A, Hopfenmueller W, Holthaus B, Köhler C, Schneider A, Hasenbein K, Chiantera V. Laparoscopic temporary clipping of uterine artery during laparoscopic myomectomy. Arch Gynecol Obstet. 2012 ;286(5):1181-6
9.Schneider A, Erdemoglu E, Chiantera V, Reed N, Morice P, Rodolakis A, Den- schlag D, Kesic V. Clinical recommendation radical trachelectomy for fertility preservation in patients with early- stage cervical cancer. Int J Gynecol Cancer. 2012 ;22(4):659-66.
10.Erdemoglu E, Güney M, Take G, Giray SG, Mungan T. RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia. Int J Gynecol Cancer. 2009 ;19(3):375-9.
11.Erdogan M, Erdemoglu E, Evrimler Ş, Hanedan C, Şengül SS. Prognostic value of metabolic tumor volume and total lesion glycolysis assessed by 18F-FDG PET/CT in endometrial cancer. Nucl Med Commun. 2019 Nov;40(11):1099-1104.
12.Yalcin Y, Tatar B, Erdemoglu E, Erdemoglu E. The parameters to estimate postop- erative severe complications classified through Clavien-Dindo after upper abdomi- nal surgery in patients with
primary and recurrent ovarian cancer. Ginekol Pol. 2019;90(10):557-564.
13.Ceviker K, Erdemoglu E. Things may not go as planned; The role of aortoiliac dilation and elongation during the estimation vascular structures' anatomical course. Gyn Oncology Case Reports 2017;Epud.
14.Sevi̇ m Sureẏya Cerci, Kemal Kursat Bozkurt, Hasan Erol Eroglu,
Celal Cerci, Evri m Erdemoglu, Pinar Talip Bulbul, Meltem Cetin, Recep Cetin, Ibrahim Metin Ciris, Mahmut Bulbul. Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer. Oncology Letters. 2016;page 3889-3895
15.Tatar B, Yalçın Y, Bozkurt KK, Erdemoglu E, Kapucuoglu N, Erdemoglu E.
Uterine Tumors resembling ovarian sex cord tumors: a case report with adeno- myosis and complex hyperplasia with atypia. EJGO 2016;5: 726-728.
16.Bozkurt KK, Yalçın Y, Erdemoğlu E, Tatar B, Erdemoğlu E, Çerçi SS, Çiriş İM, Başpınar Ş, Uğuz A, Kapucuoğlu N. The role of immunohistochemical adrenomedullin and Bcl-2 expression in development of type-1 endometrial adeno- carcinoma: Adrenomedullin expression in endometrium. Pathol Res Pract. 2016 Feb 27. pii: S0344-0338(16)30031-0
17.Koca D, Yıldız S, Soyupek F, Günyeli İ, Erdemoglu E, Soyupek S, Erdemoglu E. Physical and mental workload in single-incision laparoscopic surgery and conventional laparoscopy. Surg Innov. 2015
;22(3):294-302.
18.Vercellino GF, Erdemoglu E, Chiantera V, Malak AH, Vasiljeva K, Drechsler I, Dückelmann AM, Richter J, Schneider A, Böhmer G. A multicentric randomized study comparing two techniques of
magnification assisted loop excision of high- grade cervical intraepithelial neoplasia: video exoscopy and colposcopy. Arch Gy- necol Obstet. 2014 ;289(6):1301-7.
19.Vercellino GF, Erdemoglu E, Chiantera V, Vasiljeva K, Malak AH, Schneider A, Böhmer G. Clinical relevance of objectifying colposcopy. Arch Gynecol Obstet. 2015 ;291(4):907-15.
20.Vercellino GF, Erdemoglu E. What should be the goal for future development of colposcopy? Cons and pros of sensitivity and specificity. Arch Gynecol Obstet. 2015 ;291(4):713-4.
21.Cerci SS, Erdemoglu E, Bozkurt KK, Yalçın Y, Erdemoglu E. Placental- site trophoblastic tumor and 18-fluorodeoxyglucose positron emission to- mography/computed tomography. Hell J Nucl Med. 2015
22.Özgönen H, Erdemoglu E, Günyeli I, Güney M, Mungan T. Comparison of the ef- fects of laparoscopic bipolar electrocoagulation and intracorporeal suture application to ovarian reserve in benign ovarian cysts. Arch Gynecol Obstet. 2013 ;287(4):729-32.
23.Günyeli I, Bozkurt KK, Yalçın Y, Tatar B, Cerçi SS, Erdemoğlu E. Granu- losa cell tumor and concurrent endometrial cancer with (18)F-FDG uptake. Hell J Nucl Med. 2014 ;17(2):153-5.
24.Vercellino GF, Chiantera V, Gaßmann J, Erdemoglu E, Drechsler I, Frangini S, Schneider A, Böhmer G. Prospective Comparison of Loop Excision under
Colposcopic Guidance versus Vitom Guidance. Geburtshilfe Frauenheilkd. 2012 ;72(10):945-948.
25.Chiantera V, Erdemoglu E, Vercellino G, Straube M, Schneider A. Laparoscopic management of external iliac artery injury using yasargil clamps and intracorporeal suture. J Minim Invasive Gynecol. 2011 ;18(4):516-9.
26.Erdemoglu E, Seçkin B, Günyeli I, Güney M, Seçkin M, Mungan T. Reduction of postoperative adhesions by trimetazidine: an experimental study in a rat model. Arch Gynecol Obstet. 2012 ;285(3):757-61.
27.Günyeli I, Abike F, Dünder I, Aslan C, Tapısız OL, Temizkan O, Payaslı A, Erdemoğlu E. Chlamydia, Mycoplasma and Ureaplasma infections in infertile couples and effects of these infections on fertility. Arch Gynecol Obstet. 2011;283(2):379-85.
28.Guney M, Erdemoglu E, Mungan T. Selenium-vitamin E combination and melatonin modulates diabetes- induced blood oxidative damage and fetal out- comes in pregnant rats. Biol Trace Elem Res.2011;143(2):1091-102
29.Cerci SS, Yalcin Y, Bozkurt KK, Erdemoglu E, Tatar B, Erdemoglu E. Hypoxia-inducible factor-1α, adrenomedullin and Bcl-2 although expect- ed are not related to increased uptake of fluorine-18-fluorodeoxyglucose in endometrial cancer. Hell J Nucl Med. 2015 Sep-Dec;18(3):228-32
30.Erdemoglu E, Güney M, Giray SG, Take G, Mungan T. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2009;145(2):195-9.
31.Sezik M, Aslan M, Orhan DD, Erdemoglu E, Pekcan M, Mungan T, Sezik E. Im- proved metabolic control and hepatic oxidative biomarkers with the periconception use of Helichrysum plicatum ssp. plicatum. J Obstet Gynaecol. 2010 Feb;30(2):127
32.Erdemoglu E, Güney M, Karahan N, Mungan T. Expression of cyclooxygenase-2, matrix metalloproteinase-2 and matrix metalloproteinase-9 in premenopausal and postmenopausal endometrial polyps. Maturitas. 2008 Mar 20;59(3):268-74.
33.Erdemoglu E, Güney M, Keskin B, Mungan T. Tamoxifen and giant endome- trial polyp.Eur J Gynaecol Oncol. 2008;29(2):198-9.
31. Güney M, Erdemoglu E, Oral B, Karahan N, Mungan T. Leukemia in- hibitory factor (LIF) is immunohistochemically localized in tubal ectopic pregnancy. Acta Histochem. 2008;110(4):319-23.
32.Erdemoglu E, Güney M, Karahan N, Mungan T. Immunohistochemical expres- sion of MMP-2, MMP-9 and COX-2 in Stage IA malignant polyps of the en- dometrium. Eur J Gynaecol Oncol. 2008;29(5):444-9.
33.Erdemoglu E, Kamaci M. Giant bladder leiomyoma presenting as a pelvic mass: a case report. Eur J Gynaecol Oncol. 2007;28(6):509-10.
34.Erdemoglu E, Ozen S. Ovarian gonodoblastoma with yolk sac tumor in a young 46, XX female: case report. Eur J Gynaecol Oncol. 2007;28(6):516-8.
35.Kelekçi S, Erdemoglu E, Kutluk S, Yilmaz B, Savan K. Risk factors for tubal liga- tion: regret and psychological effects impact of Beck Depression Inventory. Con- traception. 2005 ;71(6):417-20.
36.Erdemoglu E, Kamaci M, Ozen S, Sahin HG, Kolusari A. Ovarian heman- gioma with elevated CA125 and ascites mimicking ovarian cancer. Eur J Gy- naecol Oncol. 2006;27(2):195-6.
37.Kelekci S, Erdemoglu E, Inan I. Randomized study on the effect of adding oxy- tocin to ethacridine lactate or misoprostol for second- trimester termination of pregnancy. Acta Obstet Gynecol Scand. 2006;85(7):825-9.
38.Erdemoglu E, Kamaci M, Bayram I, Güler A, Güler Sahin H. Primary giant leiomyoma of the ovary--case report. Eur J Gynaecol Oncol. 2006;27(6):634-5
39.Erdemoglu E, Mungan T, Tapisiz OL, Ustunyurt E, Caglar E. Effect of inter-twin delivery time on Apgar scores of the second twin. Aust N Z J Obstet Gynaecol.
2003;43(3):203-6
40.Doğanay M, Erdemoglu E, Avşar AF, Aksakal OS. Maternal serum levels of dehy- droepiandrosterone sulfate and labor induction in postterm pregnancies. Int J Gy- naecol Obstet. 2004;85(3):245-9.
41.Erdemoglu E, Mungan T. Significance of detecting insulin-like growth factor binding protein-1 in cervicovaginal secretions: comparison with nitrazine test and amniotic fluid volume assessment. Acta Obstet Gynecol Scand. 2004;83(7):622- 6.
42Erdemoglu E, Aydogdu T, Tokyol C. Primary retro peritoneal mucinous cystadeno- ma. Acta Obstet Gynecol Scand. 2003;82(5):486-7.
Publications in Journals in other indexes and national publications
1.Biçer Ç, Raoufi J, İşcan SC, Güney M, Erdemoğlu E. Surgical risk assessment for gynecological oncologic patients. Turk J Obstet Gynecol. 2019 Sep;16(3):158-163. doi: 10.4274/ tjod.galenos.2019.93584. Epub 2019 Oct 10.
2.Erdemoglu E. Cytoreductive Surgery in Ovarian Cancer. Türkiye Klinikleri; Özel Sayısı.
3.Primary Extra-Gastrointestinal Stromal Tumor of Mesenteric Root: a Rare Version of a Soft Tissue Tumor Located on a Critical Region. Yalcin Y, Bozkurt KK, Ciris IM, Cerci SS, Erdemoglu E. J Gastrointest Cancer. 2017.
4.Tatar B, Oksay T, Cebe FS, Soyupek S, Erdemoglu E. Vesicovaginal fistulas after gynecologic surgery. TJOG. 2017; 14(1):45-52.
5.Yalçın Y, Tatar B, Erdemoglu E, Akkurt M, Yavuz A, Erdemoglu E. Laparoscopic systemic devascularization of uterine cornu for cornual resection in interstitial pregnancy. Turk J Obstet Gynecol 2015; 12: 182-184
6.Tola EN, Erdemoglu E, Erdemoglu E. Uterine sparing surgical methods in pelvic organ prolapse. Turk J Obstet Gynecol 2015; 12: 168-172.
7.Schneider A, Gleizes O, Niemen P, Erdemoglu E, Boselli F, Jenkins D. Implica- tions of varied patterns of cervical cancer screening for introduction of human papillomavirus vaccines in Europe. J Turk Ger Gynecol Assoc 2009; 10: 61-67
8.Sengül OB, Mungan T, Erdemoğlu E, Islamoğlu G, Kıyak N. Investigation of the correlation between 100 gram oral glucose tolerance test results and mater-
nal leptin levels during pregnancy. J Turk Ger Gynecol Assoc. 2009 1;10(3):158-61.
9.Erdemoglu E, Yıldızhan R, Kurdoglu M, Adalı E, Kamacı M. Jinekolojik la- paroskopi esnasında ana damar yaralanması: olgu sunumu. Marmara Medical Journal 2009; 22(2):138-141
10.Erdemoglu E, Ugur M, Erdemoglu E. Plasma homocysteine and nitric ox- ide levels in preeclampsia. J Turkish-German Gynecol Assoc 2009; 10: 26-9
11.Antalyalı M, Erdemoglu E, Güney M, Oral HB, Bayhan G, Mungan T. Sekonder Abdominal gebelik. Kadın Doğum Dergisi 2008; 7(1): 1585-1587
12.Erdemoglu E, Kamacı M. Correlation of ultrasonography and MRI in prenatal diagnosis of lobar holoprosencephaly. Gynecology Obstetrics and Reproductive Medicine, 2008; 14(1): 41-44
13.Erdemoglu E, Özmen E. Complicated vesicourethravaginal fistula. J Turkish- German Gynecol Assoc 2008; 9(4): 240-242.
14.Mungan T, Erdemoglu E. Gebelik ve diabetes mellitus. Türkiye Klinikleri Jinekoloji Obstetrik 2008; 1(2): 46-60.
15.Güney M, Erdemoglu E, Mungan T. Wernike ensfalopatisiyle komplike hipereme- sis gravidarum. TJOD 2008; 5(2): 134-136.
16.Erdemoglu E, Özdemir H, Küçükaydın Z, Kamacı M. Burst strength of small bowel sealed by feedback controlled vessel sealing device, three layer suture and reinforcement with amniotic membrane. Jinekoloji Obstetrik Neonatoloji Tıp Dergisi 2007; 4(14): 515-518
17.Mungan T, Erdemoglu E, Güney M. The effect of ultrasonographically deter- mined tubal implantation site in ectopic pregnancy on success of methotrexate treatment and subsequent reproductive outcome. J Turkish- German Gynecol Assoc 2007; 8(4): 387-392
18.Güney M, Erdemoglu E, Mungan T. Tubaovaryan abse: 25 olgu analizi ve literatür derlemesi. Kadın Doğum Dergisi 2007; 5(4):1210-1213
19.Güney M, Erdemoglu E, Çavuş Y, Bayhan G, Mungan T. İkinci trimester genetik amniosentez: 132 olgunun değerlendirilmesi. Kadın Doğum Dergisi 2007; 6(1): 1313-1318
20.Erdemoglu E, Kolusarı A, Şahin H, Kamacı M. Familial imperfore hymen. J Turkish-German Gynecol Assoc 2007; 8(1): 88-89
21.Erdemoglu E, Güney M, Mungan T. Jinekolojik laparoskopide pneu- moperitoneum tekniklerinin karşılaştırılması. Jinekoloji - Obstetrik ve Neonatoloji Tıp Dergisi 2007; 4(14): 515-518
22.Erdemoglu E, Güney M, Mungan T. Amniotic fluid dicarboxylic acid in thanatophoric dysplasia type I. Jinekoloji - Obstetrik ve Neonatoloji Tıp Der- gisi 2007; 4(14):515
23.Erdemoglu E, Güney M, Mungan T. Biochemical markers in the vaginal wash-
ing and insulin like growth factor binding protein in the diagnosis of membrane rupture. Gynecology Obstetrics and Reproductive Medicine 2007; 13(2):76-80
24.Erdemoglu E, Erdemoglu E, Gun İ, Mungan T. Effect of delivery mode on the perinatal outcome in twin gestation. J Turkish-German Gynecol Assoc 2007; 8(2):168-171
25.Erdemoglu E, Kolusarı A, Şahin HG, Kamacı M. Prenatal ureteropelvik ob- strüksiyon tanısı ve fetal renal fonksiyonların değerlendirilmesi. Jinekoloji ve Obstetrik Dergisi 2006; 20(4): 238-241
26.Erdemoglu E. Postmenopozal dönemde kalsiyum ve vitamin D. Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi 2006; 2(35): 37-40
27.Mungan T, Erdemoglu E, Çelen Ş. Efficiency of a modified suture technique for cervical incompetence. Gynecology Obstetrics and Reproductive Medicine 2005; 11(3): 176-179
28.Erdemoglu E, Okyay E, Tapısız OL, Avşar AF. Fetal liver length measurement. Gynecology Obstetrics and Reproductive Medicine 2003; 9(2): 79-82
29.Doğanay M, Erdemoglu E, Yüksel K, Dilara T. Dev abdominal duvar desmoid tümörü. Türkiye Klinikleri Jinekoloji ve Obstetrik 2003; 13(5):387-389
30.Erdemoglu E, Erdemoglu E, Avşar AF. Transvers duruşların klinik özellikleri ve risk faktörleri. Kırıkkale Üniversitesi Tıp Dergisi 2003; 4(3): 38-40
31.Tokyol Ç, Erdemoglu E, Gökmen O. Mol hidatiform ve hidropik abortuslar. Jinekoloji Onkoloji 2001; 4(1): 38-43
32.Doğanay M, Aksakal OS, Erdemoglu E, Özcan U, Gökmen O. Gebelik ve puerperium sırasında venöz tromboembolizmin insidansı. Tıp ve Sağlık Der- gisi 1999; 3(2): 77-81
33.Erdemoglu E, Güney M, Çimen T, Mungan T. serum zinc concentration and he- licobacter pylori serology in hyperemesis gravidarum. Gynecol Obstet Reprod Med 2009; 15(2): 67-69
34.Gunyeli I, Erdemoglu E, Bulbul M, Mungan T, Kapucuoğlu N. Adolesan Bir Kızda Pelvik Nöroganglioma: Son Derece Nadir Bir Olgu. Turkiye Klinikleri J Gynecol Obst 2012;22(3): 195-8.
35.Güler A, Sahin HG, Küçükaydın Z, Erdemoğlu E. Comparison of the efficacy of
intrauterine lidocaine, paracervical block and oral etodolac for decreasing pain in endometrial biopsy. J Turk Ger Gynecol Assoc. 2010 1;11(4):178-81
36.Şengül Ö, Mungan T, Erdemoglu E, İslamoglu G, Cantürk F. Cord blood leptin levels in gestational diabetes. Gynecol Obstet Reprod Med 2010; 16(2): 70-75
37.Erdemoglu E, Günyeli İ, Güney M, Oral B, Bayhan G, Mungan T. Abdominal histerektomi sonrası vajinal eviserasyon. J Turk Soc Obstet Gynecol, 2011; 8(2): 149- 52
38.Dilmen E, Günyeli I, Oral B, Erdemoğlu E, Güney M, Bayhan G, Mungan T. Serum Yüksek Dansiteli Lipoprotein ve Sfingozin 1 Fosfat Düzeylerinin, Hipertansif ve Normotansif Gebelikler Arasında Karşılaştırılması. J Turk Soc Obstet Gynecol 2011; 8(3): 164- 8
39.Erdemoğlu E, Günyeli I, Kamacı M, Mungan T. Adnexial Mass in the Adoles- cents. Gynecology Obstetrics & Reproductive Medicine 2011; 17:1:39-41.
40.Gunyeli I, Erdemoglu E, Guney M, Mungan T. İki Akrani Vakasının Değer- lendirilmesi: Olgu Sunumu. Kadin Dogum Dergisi. 2010;9(1): 2005-9.
41.Erdemoglu E, Gunyeli I, Mungan T. Subtotal Histerektomi Sonrası Endome- trial Stromal Sarkom: Olgu Sunumu. Kadın Doğum Dergisi. 2010;9(2):2071-73.
42.Erdemoglu E, Gunyeli I, Guney M, Kiremitci S, Sertcelik A, Mungan T. Endometrial polip'den gelişen Adenosarkoma (Rhabdomyosarkoma). Türk Jinekolojik Onkoloji Dergisi. 2011;3 (14):81-85.
43.Gunyeli I, Erdemoglu E, Alanoglu G, Mungan MT. Beta Talasemi Major'e Sekon- der Gonadal Disfonksiyon ve Hipogonadotropik Hipogonadizm: İki vaka takdimi. Kadın Doğum Dergisi. 2011;10(1):2305-2310.
44.Gunyeli I, Erdemoğlu E, Ortak T, Mungan T. Edinilmiş Kloaka'da anal sfink- teroplasti ve lokal rotasyon flebiyle perineoplasti yöntemi. S.D.Ü. Tıp Fak. Derg. 2012;19(1):170-173.
45.Gunyeli I, Erdemoglu E, Guney M, Mungan T. Yirmi altı Haftalık Gebelik- te Preeklampsiye Sekonder Posterior Reversibıl Ensefalopati Sendromu (PRES): Bir olgu Sunumu. JOPP Derg. 2012;4(2):80-84.
46.Günyeli İ, Erdemoglu E. Human papilloma virus tanısı, tedavisi ve hastalıktan korunma. Actual Medicine 2010; 18(7): 33-36
47.Günyeli I, Erdemoğlu E, Ceylaner S, Zergeroğlu S, Mungan T. Histopathological analysis of the placental lesions in pregnancies complicated with IUGR and still- births in comparison with noncomplicated pregnancies. J Turkish-German Gynecol Assoc 2011; 12(2): 75
48.Özkan EE, Erdemoğlu E, Raoufi J. Impact of diabetes on gastrointestinal and urinary toxicity after radiotherapy for gynecologic malignancy. Turk J Obstet Gy- necol. 2019 Dec;16(4):260-265. doi: 10.4274/tjod.galenos.2019.56957. Epub 2020 Feb 28.
49.Akkuş F, İşcan SC, Raoufi J, Güney M, Erdemoğlu E. Effect of using magnifying loupe glasses on lymphocele formation and surgical outcomes in gynecologic on- cology. Turk J Obstet Gynecol. 2019 Dec;16(4):255-259. doi: 10.4274/ tjod.galenos.2019.93467. Epub 2020 Feb 28.
50


Hobbies:
Fitness / Bicycle / Sailing 

Gynecologic Oncology Surgery
Default avatar
Prof. Dr. Hasan YASAN SÜLEYMAN DEMİREL ÜNİVERSİTESİ
Otorhinolaryngology
Mekin Sezik
Prof. Dr. Mekin SEZİK Süleyman Demirel Üniversitesi Web
Obstetrics and Gynaecology, Foetal Development and Medicine
Sabriye Ercan
Prof. Dr. Sabriye ERCAN Suleyman Demirel University, Faculty of Medicine
Physical Activity and Health, Sports Medicine, Sport and Exercise Nutrition
Gene Expression, Genotoxicity and Cytotoxicity, Cancer Biology
Default avatar
Dr. Ülkü YAYLALI It is not affiliated with an institution Web

Özgeçmiş Formu


A. KİŞİSEL BİLGİLER
Bu bölümde verilen bilgilerin güncel ve ulaşılabilir olması gerekmektedir.
Adı soyadı: Ülkü YAYLALI ÜSER
Doğum tarihi:1978
Yabancı dil bilgisi:YÖKDİL:59 YDS:
Görev yeri: S.B.Ü ANTALYA EĞİTİM VE ARAŞTIRMA HASTANESİ
E-posta adresi:ulkuyaylali@yahoo.com
Telefon:+90 505 376 26 85

B. EĞİTİM BİLGİLERİ
Mezun olduğu üniversite/fakülteyi lütfen belirtiniz: Akdeniz üniversitesi/Tıp Fakültesi
Lisans- Tıp Fakültesi
Uzmanlık:Enfeksiyon Hastalıkları ve Mikrobiyoloji ABD
Varsa, akademik ünvanları lütfen belirtiniz: Uzm. Dr.

C. İŞ TECRÜBESİNE AİT BİLGİLER
Bugüne kadar çalıştığı kurum/kuruluşları lütfen belirtiniz:
ANTALYA 18 NOLU KÜLTÜR SAĞLIK OCAĞI /ANTALYA
AKDENİZ ÜNİVERSİTESİ ENFEKSİYON HASTALIKLARI ABD/ANTALYA KİLİS DEVLET HASTANESİ /KİLİS

D. KLİNİK ARAŞTIRMALARLA İLGİLİ GENEL BİLGİLER
Bu bölümde verilen bilgiler, tarih sıralamasına göre, en eski tarihliden yeni tarihliye doğru sıralanmalıdır.
İyi klinik uygulamaları (İKU) ve klinik araştırma konularında eğitim alınmışsa, alınan kurum/kuruluşun adı ve tarihi ile lütfen belirtiniz:     
Varsa, araştırmacı olarak katılınan klinik araştırmaları lütfen belirtiniz:

Ulusal ve Uluslararası hakemli dergilerde yayımlanan makaleler :

1. 0ktay Yapici Filiz Gunseren Hafize Yapici Alparslan Merdin Ülkü Üser Yaylali Fatma Avci Merdin Evaluation of febrile neutropenic episodes in adult patients with solid tumorsDecember 28, 2015 https://doi.org/10.3892/mco.2015.722 Pages: 379-382
2. Figen Sarıgul *, Murat Sayan, Ulku User and Nefise Oztoprak Evaluation of DirectActing Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under StrictRules Hepat Mon. 2019 March; 19(3):e62390
3. Figen Sarigul, User U, Oztoprak N COMPARISON OF IMMUNOLOGICAL AND VIROLOGICAL RECOVERY OF RALTEGRAVIR, ELVITEGRAVIR AND DOLUTEGRAVI R iN HIV-1 INFECTED NAIVE PATIENTS Acta Medica Mediterranea, 2019, 35: 3077
4. Sarigul F ,Sayan M, User U and Oztoprak N Relapse with NS5A Cross - Resistant HCV Variant after Cure Treatment with Ledipasvir/Sofosbuvir in a Turkish Patient with ChronicHepatitis C: A Case Report Clinical and Medical Case Reports 2017
5. Figen SARIGUL YILDIRIM, Ulku USER, Murat SAYAN,Nefise OZTOPRAK Does Pegylated-lnterferon Stili Have High Efficacy Treatment Properties Against ChronicHepatitis B Viral Hepatitis Journal 2018;24(3):90-9
6. Figen Sarıgül, Ülkü Üser, Nefise Öztoprak Cryptococcus neoformans Meningitis With Renal lnvolvement in an HIV-Positive Patient: A Case Report Klimik Dergisi 2018;31: 153-156
7. Figen SARIGUL YILDIRIM, Ulku USER, Nefise OZTOPRAK Seroprevalence and Risk Factors in HIV/AIDS Patients Coinfected With SyphilisKlimik Journal / Klimik Dergisi. Agu 2019, Vol. 32 lssue 2, p161-164.4p


Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

8. Ülkü ÜSER, 16-19 Kasim 2017 HIV/AIDS Kongresi 2017' de "Evaluation of Syphilis in NewlyDiagnosed HIV-1 lnfected Patients in Antalya, Turkey" başlıklı sözlü sunum
9. Ülkü ÜSER, 28-31 Mart 2018 XIX. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresine uPegile­ interferon Hala Kronik Hepatit B Tedavisinde Etkili mi?" sözlü sunum
10. Ülkü ÜSER, 26 - 29 Nisan 2018 14. Ulusal Viral Hepatit Kongresi "Relapse with NS5A cross -resistant HCV variant after cure treatment with ledipasvir/sofosbuvi r in a Turkish patient withchronic hepatitis C: A case report" sözlü sunum
11. SarıND,Taşova Y, Kaya S,Öztoprak NC,Önlen Y,Batırel A,Esen Ş,Yamazhan T, nce N,Köse S,Yı dız İE, Zerdali +EY,Karaali R, Köksal ,Günal ö,Karsen H, nan D,Coşkuner SA,Kayaaslan B,Namıduru M, Sırmatel F, GülHC, Şener A, Barut S,Duygu F, Tartar AS, Karabay O, Türker K, ÇelebiG, Şenateş E, Erben N, Sünnetçioğlu M, TosunGG, Kumbasar HK, Baykam N, Gündüz A, Akıncı E,Yörük G, nalAS,Üser Ü,Tabak F ve HEP-C Çalışma GrubuDİREK ETKİLİ ANTİVİRALLERİN TEDAVİ DENEYİMLİ KRONİK HCV ENFEKSİYONU HASTALARINDA ETKİLİLİGİ VE GÜVENLİGİ: ÇOK MERKEZLİ HEP-C ÇALIŞMASININ SONUÇLAR! 26 - 29 Nisan 2018 14. Ulusal Viral Hepatit Kongresi PS- 07 48
12. Aslıhan Candevir Ulu, Dilara İnan, Figen Sarıgül Yıldırım, Gülden Ersöz, Süheyla Kömür, Ülkü Üser Elli Yaş ve Üzeri HIV ile Enfekte Naif Hastalarda Elvitegravir / Kobisistat / Emtrisitabin / Tenofovir Alefenamid Tedavisinin Etkinliği: Gerçek Yaşam Verisi poster HIV AIDS kongresi 2019
13. Mustafa Kemal Çelen, Aslıhan Candevir Ulu, Nefise Öztoprak Çuvalcı, Gülden Ersöz, Süheyla Kömür, Ülkü Üser et al Elvitegravir/Kobisistat/Emtrisitabin/Tenofovir Alafenamid Tedavisinin Lipit Profili Üzerine Etkileri: Gerçek Yaşam Verisi poster HIV A IDS kongresi 2019
14. Dilara İnan, Aslıhan Candevir Ulu, Ülkü Üser et al TAF ile Gerçek Yaşam Deneyimi: E/C/F/TDF'ten E/C/F/TAF'a İlaç Değişimi Yapılan HIV ile Enfekte Hastalarda eGFR Verileri, Türkiye'nin Güneyinden Sonuçlar poster HIV AIDS kongresi 2019
15. Dilara İnan, Aslıhan Candevir Ulu, Ülkü Üser et al Çok Yüksek Viral Yükle Başvuran Naif HIV Hastalarında E/C/F/TAF Etkinliği poster HIV AIDS kongresi 2019
16. Dilara İnan, Aslıhan Candevir Ulu, Nefise Öztoprak Çuvalcı, Gülden Ersöz, Süheyla Kömür, Figen Sarıgül Yıldırım, Özlem Kandemir, Ferit Kuşçu, Ülkü Üser Geç Başvuran HIV Hastalarında E/C/F/Taf Etkinliği: Gerçek Yaşam Verisi poster HIV AIDS kongresi 2019

Uluslararası bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

17. Ülkü ÜSER, BUHASDER Kongresi 8.Tepecik Enfeksiyon Günleri 16-20 Ekim 2019'da 'Hastanemiz Yoğun Bakım Ünitelerinde Son 5 Yılda Görülen Hastane Kökenli Enfeksiyonlarda Gram Negatif Etken Dağılımı ve Direnç Profilleri' başlıklısözlü sunum SS-08
18. Ülkü Üser, Hande Berk, Figen Yı dırım, Filiz Kızı ateş, Nefise Öztoprak Hepatit B Virusü Ko­ enfeksiyonu Olan Bir Edinse! İmmün Yetmezl ik Sendromu Olgusunda Yaygın Kriptokok Enfeksiyonu ve Retinit 6. TÜRKİYE EKMUD KONGRESİ 11-15 MAYIS 2016 PS-295
19. Ülkü Üser, Figen Yıldırım, Hande Berk, Nefise Öztoprak HIV Enfekte Olguların Epidemiyolojik ve Klinik Özellikleri ile Antiretroviral Tedaviye Yanıtlarının Değerlendirilmesi 6. TÜRKİYE EKMUD BİLİMSEL PLATFORMU 4-8 NİSAN 2017 PS-132
20. N. Oztoprak, U. Yaylali, F. Sarigul lntegrase Strand Transfer lnhibitor Use inAntiretroviral Naive Patients - A Real Life Experience 16th European AIDS Conferance(EACS) 2017
21. 15-F Sarigul, U User and N Oztoprak Raltegravir, elvitegravir, dolutegravir comparison and CD4/CD8 ratio normalisation in HIV-infected patients HIV Glasgow 2018,28-31 October2018, Glasgow, UK
22. Nevin İnce,Nagihan Didem Sarı, Ayşe Batırel, Hasan Karsen, Süheyla Kömür, İftihar Köksal,Selçuk Kaya,İlknur Esen Yıldız, Şaban Esen , Esra Zerdali,Yusuf Önlen, Mustafa Namıduru, Dilaraİnan, Kamuran Türker, Fatma Sırmatel, Nurettin Erben, Ayhan Akbulut, Şener Barut,Nurcan Baykam, Selma Tosun, Esragül Akıncı,Şükran Köse, Fazilet Duygu,Rahmet Güner, Hanefi Cem Gül,Özgür Günal,Oğuz Karabay, Mahmut Sünnetçioğlu, Tansu yamazhan, Rıtvan Karaali, Ülkü Üser, Fehmi Tabak Türkiye' de Kronik HCV Enfeksiyonu Olan Diyabetik Hastalarda Direkt Etkili Antiviral İlaçların Etkililiği ve Güvenirliği 7. TÜRKİYE EKMUD Uluslararası Kongresi 8-13 Mayıs 2018
23. Ülkü Üser, Figen Sarıgül, Tangül Pınarcı Kronik Hepatit C Tedavisi Sonrası Nüks ve HCC Gelişen Bir Olgu -BUHASDER Kongresi 8. Tepecik Enfeksiyon Günleri 16-20 Ekim 2019 PS-66
24. Ülkü Üser, Figen Sarıgül HIV İle Enfekte Bir Olguda Komorbiditelerin Yönetimi 7. Türkiye EKMUD Bilimsel Platformu 3-7 Nisan 2019
25. D. İnan. A. Candevir Ulu, F. Sarıgül Yıldırım, G.Ersöz,S.kömür,ü.üser et al The effectiveness of E/C/F/TAF in treatment- naive-experienced (TE) adult HIV-infected patients in real world setting, results from southern Turkey EACS 2019 poster

Uluslararası Kitap Bölümü
26. Ülkü Üser, AKUT VİRAL HEPATİTLER " 29. AİLE HEKİMLİGİNDE GÜNCEL YAKLAŞIMLAR" ISBN 9786052585481

Varsa, izleyici (monitör) olarak katılınan klinik araştırmaları lütfen belirtiniz:     

Varsa, saha görevlisi olarak katılınan klinik araştırmaları lütfen belirtiniz:

Varsa, araştırma eczacısı olarak katılınan klinik araştırmaları lütfen belirtiniz:     

E. ÖZGEÇMİŞ SAHİBİNİN İMZASI
Adı soyadı: Uzm.Dr. Ülkü YAYLALI ÜSER
Tarih (gün/ay/yıl olarak):09.03.2021
İmza:





1

Clinical Microbiology

Med J SDU is an international, scientific, open access, online/print journal that follows independent, unbiased, and double-blind peer-review principles.

Med J SDU publishes research in the health sciences, including original clinical and experimental studies, reviews of current topics, case reports, editorial comments, and letters to the editor. The language of the journal is English.

About Med J SDU
Medical Journal of Süleyman Demirel University (Med J SDU) is published quarterly in March, June, September and December. Med J SDU is an international, scientific, open access, online/print journal that follows independent, unbiased, and double-blind peer-review principles.
Med J SDU publishes research in the health sciences, including original clinical and experimental studies, reviews of current topics, case reports, editorial comments, and letters to the editor. The language of the journal is English.
Med J SDU is indexing in both international (EBSCO) and national (TRDizin) indexes.
There is no charges for publishing or publication process. No copyright price are payable to the authors or other third parties for the articles published in the journal. Med J SDU has adopted the policy of providing open access with the publication. Authors’ credentials and e-mail addresses are in no way used for other purposes.
The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).
Originality, high scientific quality and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization.

Ethical Principles
An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects,” amended in October 2013, www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. Ethics committee approvals or an equivalent official documents must be uploaded into the dergipark system.
• For manuscripts concerning experimental researches on humans, a “Written Informed Consent to Participate and Publish” statement should included in the text.
• Written Informed Consent to Participate Publish statement and Ethics Committee approval details (name of the committee, date and number) should included in the Materials and Methods section and in the end of the article (before references) with separate sub-headings.

• It is the authors responsibility to carefully protect the patients anonymity. For photographs that may reveal the identity of the patients, releases signed by the patient or their legal representative should be enclosed.
• For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Ethics Committee approval details (name of the committee, date and number) should included in the Materials and Methods section and in the end of the article (before references) with separate sub-headings.

A statement is required whether any kind of artificial intelligence (AI) tools are used. Authors should be transparent when AI are used and provide information about how they were used and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool (including the accuracy of what is presented and the absence of plagiarism), and are thus liable for any breach of publication ethics. AI tools cannot be listed as an author of a paper.

All submissions are screened by similarity detection software (Turnitin, iThenticate, and Intihal.net) and the similarity limitation is 25%. The Editorial Board of the journal handles all appeal and complaint cases within the scope of Committee on Publication Ethics (COPE) guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve cases that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

When submitting a manuscript to Med J SDU, authors accept to assign the copyright of their manuscript to the journal. If rejected for publication, the copyright of the manuscript is considered to be assign back to the authors. Each submission must be submitted in accordance with the journal template (available for download at: https://dergipark.org.tr/tr/download/journal-file/24521), together with a Copyright Transfer Form (available for download at: https://dergipark.org.tr/tr/download/journal-file/22117). Mandatory documents to be sent can be found at https://dergipark.org.tr/tr/pub/sdutfd.
When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s). Statements or opinions expressed in the manuscripts published in Med J SDU reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility in regard to the published content rests with the authors. Revisions should submit within 15 days in pre-review stage and in 30 days in review stage. Otherwise manuscripts will be rejected.

Manuscript Preparation

Manuscripts can only be submitted through the journal’s online manuscript submission and evaluation system, available at https://dergipark.org.tr/tr/pub/sdutfd. Manuscripts submitted via any other medium will not be evaluated. Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal’s guidelines. Submissions that do not conform to the journal’s guidelines will be returned to the submitting author with technical correction requests. The editor reserves the right to reject manuscripts that do not comply with the above-mentioned requirements. Corrections may be done without changing the main text. The editor reserves the right to reject the articles that do not meet the required conditions.

Authors are required to submit the following:
Copyright Transfer Form (Authors must use journal template)
Title Page (Authors must use journal template, must include title of manuscript, running title, authors’ name, title and institution, corresponding author’s contact information, ORCID addresses, name of the organization supporting the research and ethical approvals)
Main document (It should be prepared according to the journal template and should include a sectioned abstract; Full text file must also include tables and figures with legends alongside separate table and figure files, must be suitable for double blind review process. ).
• Figures (If applicable, Jpeg/png format, at least 300 DPI, high resolution, up to 6 figures)
• Tables (If applicable, Microsoft Word format, up to 6 table, Each table should not exceed one page)
• Ethical Approvals (If applicable)
Author Contributions (according to CRediT, please see Template, Authors must use journal template)
• Plagiarism Report (The plagiarism report uploaded by the authors must be obtained from Turnitin, iThenticate, and Intihal.net, and the similarity rate must be below 25%.)
• Language Editing Certificate (Certificate should be obtained from an institution or corporation providing this service or from a person whose main business is language services such as a sworn translator)


Preparation of the Main Document
The articles should be written with double-spaced in 12 pt, Times New Roman character and at least 2 cm from all edges of each page. The main text should not contain any information about the authors’ names and affiliations. Original articles should have a structured abstract (Objective, Material and Methods, Results, Conclusion, Keywords). For case reports and reviews, the structured abstract is not used. Limit the abstract to 300 words. References, tables and citations should not be used in an abstract. Authors must include relevant keywords (3-5) on the line following the end of the abstract. All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition. When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company, should be provided in parentheses.

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively. The symbols used must be in nomenclature standards.

Original Research
The manuscript should be no longer than 4,000 words and include no more than 40 references. The following subheadings should be included:
• Title
• Abstract
• Keywords
• Introduction
• Material and Methods
• Results
• Discussion
• Conclusions
• Statements (Please See: Template)
• References
• Figure and Table Legends (if necessary)

Case Reports The manuscript should be no longer than 2,000 words and include no more than 20 references. The following subheadings should be included:

• Title
• Abstract
• Keywords
• Introduction
• Case Presentation
• Discussion and Conclusion
• Statements (Please See: Template)
• References
• Figure and Table Legends (if necessary)

Reviews The manuscript should be no longer than 6,000 words and include no more than 80 references. The following subheadings should be included:
• Title
• Abstract
• Keywords
• Main text
• Conclusion
• Statements (Please See: Template)
• References
• Figure and Table Legends (if necessary)

Letter to Editor The manuscript should be no longer than 1,000 words and include no more than 10 references. The following subheadings should be included:

• Title
• Abstract
• Keywords
• Letter to Editor
• Statements (Please See: Template)
• References
• Figure and Table Legends (if necessary)

Preparation of the Figures and Tables
• Up to 6 Figures, graphics, or photographs can be submitted. Separate files (in JPEG format) should be submitted through the submission system and should not be embedded in a Word document. The minimum resolution of each submitted figure should be 300 DPI. Figures should be in high resolution so that the printed version can be read easily.
• Figures with legends should also be listed at main document for review.
• Information or illustrations must not permit identification of patients, and written informed consent for publication must be sought for any photograph.
• Up to 6 tables can be submitted. Each table should not exceed one page. Tables should be listed at main document for review.
• All tables and figures should be numbered consecutively. 

References
All references should be numbered consecutively in Vancouver style. If more than two consecutive resources are used, only the first and last source numbers should be specified (for example; 2-6). Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus. When there are 3 or fewer authors, all authors should be listed. If there are 4 or more authors, the first 3 authors should be listed followed by “et al.” The reference styles for different types of publications are presented in the following examples:

For journals;
Neville K, Bromberg A, Bromberg S, el al. The third epidemic multidrug resistant tuberculosis. Chest 1994;1(4):45-8. 555

For books;
Sweetman SC. Martindale the Complete Drug Reference. 34th ed. London: Pharmaceutical Press; 2005.

For book section;
Collins P. Embryology and development, Neonatal anatomy and growth. In: Williams PL, Bannister LH, Berry MM, Collins P, Dyson M, Dussek JE, Ferguson MWJ. Gray’s Anatomy (38th Ed) London, Churchill Livingstone, 1995; 91-342.

For website;
Gaudin S. How moon landing changed technology history [Internet]. Computerworld UK. 2009 [cited 15 June 2014]. Available from: http://www.computerworlduk.com/in-depth/it-business/2387/how-moon-landing-changed-technology-history/

For conference proceeding;
Brom A. Robotics and Mechatronics. Symposium on Robotics, Mechatronics and Animatronics in the Creative and Entertainment Industries and Arts. SSAISB 2005 Convention. University of Hertfordshire, Hatfield, UK; 2005.

For Thesis;
Ercan S. Venöz yetmezlikli hastalarda kalf kası egzersizlerinin venöz fonksiyona ve kas gücüne etkisi. Suleyman Demirel University Faculty of Medicine Sports Medicine Department Thesis. Isparta: Suleyman Demirel University. 2016.


Retraction or Reject
Manuscript Retraction: Authors may withdraw their manuscript from the journal with a written declaration with detailed reason only before DOI assigned. If a DOI has been assigned to the article, it can no longer be withdrawn by the authors.

Manuscript Reject: Editors have the authority to reject articles at any stage of the article process.

After Acceptance
If the manuscript is accepted, the acceptance letter and the last version of manuscript are sent to corresponding author through submission system. The journal board is authorized to decide in which volume of the accepted article will be printed. Authors may publish their articles on their personal or corporate websites with the appropriate cite and library rules after publication.

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects,” amended in October 2013, www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. Ethics committee approvals or an equivalent official documents must be uploaded into the dergipark system.
• For manuscripts concerning experimental researches on humans, a “Written Informed Consent to Participate and Publish” statement should included in the text.
• Written Informed Consent to Participate Publish statement and Ethics Committee approval details (name of the committee, date and number) should included in the Materials and Methods section and in the end of the article (before references) with separate sub-headings.
• It is the authors responsibility to carefully protect the patients anonymity. For photographs that may reveal the identity of the patients, releases signed by the patient or their legal representative should be enclosed.
• For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Ethics Committee approval details (name of the committee, date and number) should included in the Materials and Methods section and in the end of the article (before references) with separate sub-headings.
• A statement is required whether any kind of artificial intelligence (AI) tools are used. Authors should be transparent when AI are used and provide information about how they were used and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool (including the accuracy of what is presented and the absence of plagiarism), and are thus liable for any breach of publication ethics. AI tools cannot be listed as an author of a paper.


All submissions are screened by a similarity detection software (Turnitin, iThenticate, and Intihal.net) and the similarity limitation is 25%. The Editorial Board of the journal handles all appeal and complaint cases within the scope of Committee on Publication Ethics (COPE) guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve cases that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

When submitting a manuscript to Med J SDU, authors accept to assign the copyright of their manuscript to the journal. If rejected for publication, the copyright of the manuscript is considered to be assign back to the authors. Each submission must be submitted in accordance with the journal template (available for download at: https://dergipark.org.tr/tr/download/journal-file/24521), together with a Copyright Transfer Form (available for download at: https://dergipark.org.tr/tr/download/journal-file/22117). Mandatory documents to be sent can be found at https://dergipark.org.tr/tr/pub/sdutfd.
When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s). Statements or opinions expressed in the manuscripts published in Med J SDU reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility in regard to the published content rests with the authors. Revisions should submit within 15 days in pre-review stage and in 30 days in review stage. Otherwise manuscripts will be rejected

There is no charges for publishing or publication process. No copyright price are payable to the authors or other third parties for the articles published in the journal.

                                                                                               14791 


Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi/Medical Journal of Süleyman Demirel University is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International.